Scientists at Stanford University have developed genetically engineered mice with partially human brains by transplanting lab-grown human brain tissue into rodents bred to lack key brain regions. The breakthrough aims to provide a new model for studying human neurological disorders such as schizophrenia, epilepsy, cerebral palsy, intellectual disability, and rare dementias.

Researchers first created clusters of human brain cells, known as organoids, from reprogrammed stem cells derived from donated skin samples. These organoids mimic aspects of the cerebral cortex, the brain region involved in higher cognitive functions such as language, decision-making, and attention. To accommodate the transplanted human tissue, the team genetically modified mice so that major portions of their own cortex and hippocampus—critical areas for cognition and memory—did not develop. Shortly after birth, the human brain organoids were injected into the mice where the missing mouse brain tissue would have been.

Three months after the transplantation, the human tissue had integrated with the mouse brain, connecting to the animals’ blood supply and occupying roughly half the volume of the rodents’ brains. Some human neurons formed synaptic connections with mouse brain and spinal cord cells. While the human brain tissue remained immature—equivalent to that seen mid-gestation in humans—and was not organized identically to a fully developed human brain, the animals exhibited modest improvements in cognitive tasks and gait compared to control mice.

This xenocortical mouse model offers researchers the ability to study human brain development and disease processes within a living organism. For example, the team subjected some mice to low-oxygen conditions mimicking birth complications and observed vulnerabilities in the human neurons, providing insight into conditions like cerebral palsy. Additionally, the presence of rare von Economo neurons, which are implicated early in frontotemporal dementia, opens new avenues to study this and other neurodegenerative diseases in vivo.

While the research holds promise for advancing understanding and treatment of neurological and psychiatric disorders, it also raises ethical questions. Concerns have been voiced regarding animal welfare and the potential for human brain tissue in animals to develop consciousness or experience pain. The research team emphasized that the work was conducted under strict ethical oversight and called for ongoing monitoring. Legal and ethical experts underline the importance of carefully evaluating the impact on the animals involved.

Some experts highlight that while this approach may advance studies requiring whole-animal models, it remains an artificial system that differs significantly from natural human brain development. Many scientists in the field continue to pursue fully in vitro organoid models as alternatives to reduce animal use. Nonetheless, this work may inform improvements to such lab-grown models and deepen understanding of brain disorders that have been difficult to study due to limited access to living human tissue.

The development represents a significant step forward in neuroscience, providing a novel tool to bridge gaps in current research while underscoring the need for balanced ethical consideration in emerging biotechnologies.